Santa Ana Bio Announces First Subjects Dosed in Phase 1 Study of SAB01 to Treat Autoimmune Inflammatory Diseases

Phase 1SAB01Positive

AI Analysis

Summary

Santa Ana Bio announced first subjects dosed in a Phase 1 study of SAB01, a first-in-class bispecific antibody targeting KIT and Siglec-6 for mast cell depletion in autoimmune inflammatory diseases.

Clinical Trial Data

Phase

Phase 1

Importance:4/10

Sentiment:

0.30

Phase 1bispecific antibodymast cell depletionautoimmunefirst-in-classKIT targetingSiglec-6 targeting

Related Companies

$TRAX

Read the original article

Published by GlobeNewswire Clinical Studies on September 14, 2026 12:08 PM

Read Original